Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway
Identifieur interne : 000810 ( Ncbi/Merge ); précédent : 000809; suivant : 000811Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway
Auteurs : Jie Zhu [République populaire de Chine] ; Ya Zheng [République populaire de Chine] ; Haiyan Zhang [République populaire de Chine] ; Yanmei Liu [République populaire de Chine] ; Hong Sun [République populaire de Chine] ; Pengnan Zhang [République populaire de Chine]Source :
- American Journal of Translational Research [ 1943-8141 ] ; 2019.
Abstract
Background: It has been reported that Galectin-1 (Gal-1) indicates bad prognosis of patients with ovarian cancer, and Gal-1 overexpression promotes metastasis of ovarian cancer cells. Nevertheless, the underlying mechanisms of the Gal-1-mediated enhancement of metastasis are still unclear. Furthermore, little is known about whether Gal-1 affects epithelial-mesenchymal transition (EMT) in ovarian cancer. Methods: The human SKOV3-ip and SKOV3 cell lines were transfected with Gal-1 siRNAs and LV-Gal-1 lentivirus, respectively. Cell migration and cell invasion abilities were examined by transwell assays. Protein or mRNA levels of Gal-1, p-JNK1/2, t-JNK1/2, p-p38, t-p38 and EMT markers were detected via immunohistochemistry, qRT-PCR and western blot in SKOV3-ip as well as SKOV3 cells. A xenograft tumour model was used in vivo to ascertain whether upregulation of Gal-1 in ovarian cancer cells can enhance metastasis in vivo. Results: In a total of 107 human ovarian cancer tissues, higher Gal-1 expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage, while lower E-cadherin expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage. In vitro assays revealed that Gal-1 promoted migration and invasion of ovarian cancer cells, as well as EMT. Additionally, the results showed that Gal-1 enhanced EMT, migration and invasion by activating the MAPK JNK/p38 signalling pathway. Moreover, in vivo bioluminescence imaging revealed that Gal-1 modulated ovarian cancer metastasis in nude mice. Immunochemistry of xenograft tumour tissues confirmed that Gal-1 may modulate metastasis and EMT via the MAPK JNK/p38 signalling pathway. Additionally, treatment of Gal-1 mice with the MAPK JNK/p38 signalling pathway antagonists SB203580 or SP600125 reduced cancer metastasis. Conclusion: Gal-1 enhances metastasis and EMT of ovarian cancer cells via promoting the activation of the MAPK JNK/p38 signalling pathway, suggesting the possibility that Gal-1 is a molecular target to prevent and cure ovarian cancer metastasis.
Url:
PubMed: 31312395
PubMed Central: 6614631
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000354
- to stream Pmc, to step Curation: 000354
- to stream Pmc, to step Checkpoint: 000745
Links to Exploration step
PMC:6614631Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway</title><author><name sortKey="Zhu, Jie" sort="Zhu, Jie" uniqKey="Zhu J" first="Jie" last="Zhu">Jie Zhu</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Zheng, Ya" sort="Zheng, Ya" uniqKey="Zheng Y" first="Ya" last="Zheng">Ya Zheng</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Haiyan" sort="Zhang, Haiyan" uniqKey="Zhang H" first="Haiyan" last="Zhang">Haiyan Zhang</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Yanmei" sort="Liu, Yanmei" uniqKey="Liu Y" first="Yanmei" last="Liu">Yanmei Liu</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Pengnan" sort="Zhang, Pengnan" uniqKey="Zhang P" first="Pengnan" last="Zhang">Pengnan Zhang</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31312395</idno><idno type="pmc">6614631</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614631</idno><idno type="RBID">PMC:6614631</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000354</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000354</idno><idno type="wicri:Area/Pmc/Curation">000354</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000354</idno><idno type="wicri:Area/Pmc/Checkpoint">000745</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000745</idno><idno type="wicri:Area/Ncbi/Merge">000810</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway</title><author><name sortKey="Zhu, Jie" sort="Zhu, Jie" uniqKey="Zhu J" first="Jie" last="Zhu">Jie Zhu</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Zheng, Ya" sort="Zheng, Ya" uniqKey="Zheng Y" first="Ya" last="Zheng">Ya Zheng</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Haiyan" sort="Zhang, Haiyan" uniqKey="Zhang H" first="Haiyan" last="Zhang">Haiyan Zhang</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Yanmei" sort="Liu, Yanmei" uniqKey="Liu Y" first="Yanmei" last="Liu">Yanmei Liu</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Pengnan" sort="Zhang, Pengnan" uniqKey="Zhang P" first="Pengnan" last="Zhang">Pengnan Zhang</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai 200011</wicri:regionArea></affiliation></author></analytic><series><title level="j">American Journal of Translational Research</title><idno type="eISSN">1943-8141</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Background: It has been reported that Galectin-1 (Gal-1) indicates bad prognosis of patients with ovarian cancer, and Gal-1 overexpression promotes metastasis of ovarian cancer cells. Nevertheless, the underlying mechanisms of the Gal-1-mediated enhancement of metastasis are still unclear. Furthermore, little is known about whether Gal-1 affects epithelial-mesenchymal transition (EMT) in ovarian cancer. Methods: The human SKOV3-ip and SKOV3 cell lines were transfected with Gal-1 siRNAs and LV-Gal-1 lentivirus, respectively. Cell migration and cell invasion abilities were examined by transwell assays. Protein or mRNA levels of Gal-1, p-JNK1/2, t-JNK1/2, p-p38, t-p38 and EMT markers were detected via immunohistochemistry, qRT-PCR and western blot in SKOV3-ip as well as SKOV3 cells. A xenograft tumour model was used in vivo to ascertain whether upregulation of Gal-1 in ovarian cancer cells can enhance metastasis in vivo. Results: In a total of 107 human ovarian cancer tissues, higher Gal-1 expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage, while lower E-cadherin expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage. In vitro assays revealed that Gal-1 promoted migration and invasion of ovarian cancer cells, as well as EMT. Additionally, the results showed that Gal-1 enhanced EMT, migration and invasion by activating the MAPK JNK/p38 signalling pathway. Moreover, in vivo bioluminescence imaging revealed that Gal-1 modulated ovarian cancer metastasis in nude mice. Immunochemistry of xenograft tumour tissues confirmed that Gal-1 may modulate metastasis and EMT via the MAPK JNK/p38 signalling pathway. Additionally, treatment of Gal-1 mice with the MAPK JNK/p38 signalling pathway antagonists SB203580 or SP600125 reduced cancer metastasis. Conclusion: Gal-1 enhances metastasis and EMT of ovarian cancer cells via promoting the activation of the MAPK JNK/p38 signalling pathway, suggesting the possibility that Gal-1 is a molecular target to prevent and cure ovarian cancer metastasis.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Transl Res</journal-id><journal-id journal-id-type="iso-abbrev">Am J Transl Res</journal-id><journal-id journal-id-type="publisher-id">ajtr</journal-id><journal-title-group><journal-title>American Journal of Translational Research</journal-title></journal-title-group><issn pub-type="epub">1943-8141</issn><publisher><publisher-name>e-Century Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31312395</article-id><article-id pub-id-type="pmc">6614631</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Ya</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Haiyan</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yanmei</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Pengnan</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><aff id="au1"><label>1</label><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution><addr-line>Shanghai 200011, China</addr-line></aff><aff id="au2"><label>2</label><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution><addr-line>Shanghai 200011, China</addr-line></aff></contrib-group><author-notes><corresp><bold>Address correspondence to:</bold> Drs. Pengnan Zhang and Hong Sun, Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 128 Shenyang Road, Shanghai 200011, China. Tel: +86 21 33189900; Fax: +86 21 33189900; E-mail: <email>sydzpn@163.com</email> (PNZ); <email>hongsun57@hotmail.com</email> (HS)</corresp><fn id="fn1"><label>*</label><p>Equal contributors.</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>15</day><month>6</month><year>2019</year></pub-date><volume>11</volume><issue>6</issue><fpage>3862</fpage><lpage>3878</lpage><history><date date-type="received"><day>21</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>AJTR Copyright © 2019</copyright-statement><copyright-year>2019</copyright-year></permissions><abstract><p>Background: It has been reported that Galectin-1 (Gal-1) indicates bad prognosis of patients with ovarian cancer, and Gal-1 overexpression promotes metastasis of ovarian cancer cells. Nevertheless, the underlying mechanisms of the Gal-1-mediated enhancement of metastasis are still unclear. Furthermore, little is known about whether Gal-1 affects epithelial-mesenchymal transition (EMT) in ovarian cancer. Methods: The human SKOV3-ip and SKOV3 cell lines were transfected with Gal-1 siRNAs and LV-Gal-1 lentivirus, respectively. Cell migration and cell invasion abilities were examined by transwell assays. Protein or mRNA levels of Gal-1, p-JNK1/2, t-JNK1/2, p-p38, t-p38 and EMT markers were detected via immunohistochemistry, qRT-PCR and western blot in SKOV3-ip as well as SKOV3 cells. A xenograft tumour model was used in vivo to ascertain whether upregulation of Gal-1 in ovarian cancer cells can enhance metastasis in vivo. Results: In a total of 107 human ovarian cancer tissues, higher Gal-1 expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage, while lower E-cadherin expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage. In vitro assays revealed that Gal-1 promoted migration and invasion of ovarian cancer cells, as well as EMT. Additionally, the results showed that Gal-1 enhanced EMT, migration and invasion by activating the MAPK JNK/p38 signalling pathway. Moreover, in vivo bioluminescence imaging revealed that Gal-1 modulated ovarian cancer metastasis in nude mice. Immunochemistry of xenograft tumour tissues confirmed that Gal-1 may modulate metastasis and EMT via the MAPK JNK/p38 signalling pathway. Additionally, treatment of Gal-1 mice with the MAPK JNK/p38 signalling pathway antagonists SB203580 or SP600125 reduced cancer metastasis. Conclusion: Gal-1 enhances metastasis and EMT of ovarian cancer cells via promoting the activation of the MAPK JNK/p38 signalling pathway, suggesting the possibility that Gal-1 is a molecular target to prevent and cure ovarian cancer metastasis.</p></abstract><kwd-group><kwd>Galectin-1 (Gal-1)</kwd><kwd>ovarian cancer</kwd><kwd>epithelial-mesenchymal transition (EMT)</kwd><kwd>MAPK JNK/p38 signalling pathway</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Zhu, Jie" sort="Zhu, Jie" uniqKey="Zhu J" first="Jie" last="Zhu">Jie Zhu</name></noRegion><name sortKey="Liu, Yanmei" sort="Liu, Yanmei" uniqKey="Liu Y" first="Yanmei" last="Liu">Yanmei Liu</name><name sortKey="Liu, Yanmei" sort="Liu, Yanmei" uniqKey="Liu Y" first="Yanmei" last="Liu">Yanmei Liu</name><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name><name sortKey="Zhang, Haiyan" sort="Zhang, Haiyan" uniqKey="Zhang H" first="Haiyan" last="Zhang">Haiyan Zhang</name><name sortKey="Zhang, Haiyan" sort="Zhang, Haiyan" uniqKey="Zhang H" first="Haiyan" last="Zhang">Haiyan Zhang</name><name sortKey="Zhang, Pengnan" sort="Zhang, Pengnan" uniqKey="Zhang P" first="Pengnan" last="Zhang">Pengnan Zhang</name><name sortKey="Zhang, Pengnan" sort="Zhang, Pengnan" uniqKey="Zhang P" first="Pengnan" last="Zhang">Pengnan Zhang</name><name sortKey="Zheng, Ya" sort="Zheng, Ya" uniqKey="Zheng Y" first="Ya" last="Zheng">Ya Zheng</name><name sortKey="Zheng, Ya" sort="Zheng, Ya" uniqKey="Zheng Y" first="Ya" last="Zheng">Ya Zheng</name><name sortKey="Zhu, Jie" sort="Zhu, Jie" uniqKey="Zhu J" first="Jie" last="Zhu">Jie Zhu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000810 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000810 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:6614631
|texte= Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:31312395" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |